PARP Combination Therapies: A New Horizon in Prostate Cancer Care

Join us for this interactive live symposium featuring a discussion by expert faculty on the current use of PARP inhibitors in the clinic, guidance on genetic testing to select patients for this therapy, and the latest evidence on PARP inhibitor combinations to expand their benefit. This event will offer attendees the opportunity to have their questions answered by the expert panel.

Not an official event of the 2022 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Agenda

Welcome and Introduction – Maha Hussain, MD (~10 min)

Current Use of PARP Inhibitors in Prostate Cancer – Wassim Abida, MD, PhD (~20 min)

  • Mechanism of action: synthetic lethality
  • Approved PARP inhibitor monotherapy indications
  • Unmet needs and the case for new paradigms to expand the benefit of PARP inhibition

Selecting Patients for PARP Inhibitors: Principles of Genetic Testing – Heather H. Cheng, MD, PhD (~20 min)

  • Timing of testing
  • Germline vs somatic testing
  • Tissue vs plasma testing

PARP Combinations in Prostate Cancer – Maha Hussain, MD (~25 min)

  • Rationale
  • Proof-of-principle early results
  • Phase III trials: summary of key research and near-horizon impact in the clinic

Panel Discussion and Audience Question and Answer Session (~15 min)

Events

Date / Time
Event Details

Faculty

Program Director
Maha Hussain, MD, FACP, FASCO

Genevieve Teuton Professor of Medicine
Division of Hematology/Oncology
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Faculty
Wassim Abida, MD, PhD

Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Oncology)
University of Washington
Division of Clinical Research
Fred Hutch Cancer Center
Seattle, Washington

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to understand PARP inhibitor combination mechanisms and rationale and to integrate recent findings into the management of men with prostate cancer.

Target Audience
This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select patients for treatment with currently approved PARP inhibitors by assessing DDR alterations
  • Effectively communicate to colleagues and patients the rationale for PARP inhibitor–based combinations in prostate cancer, in tumors with or without DDR alterations
  • Delineate the change in treatment sequence if phase III studies testing PARP inhibitor–based combinations for prostate cancer are positive
  • Manage adverse events associated with the use of PARP inhibitor combinations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.